Mr. Clark, are companies really interested in selling pharmaceuticals? I note that costs are minimal. You mentioned fairly complex regulatory processes. Wouldn't it be simpler to award tax credits to companies that supply pharmaceuticals? What difference would that mean in terms of cost, given that putting the required structure in place along with a renewable mandatory licensing scheme are costly propositions?
On April 16th, 2007. See this statement in context.